Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

Mini meals with bite size portions are meant to appeal to people taking GLP-1 weight-loss drugs that reduce appetite.

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Explore "The Ozempic Revolution" by Dr Alexandra Sowa—a guide to weight-loss drugs like Ozempic, their benefits, side effects ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...